Nanoformulation of bisphosphonates with a cationic peptide improves its activity against breast cancer cells

Abstract

Alendronate sodium (ALS) is one of the class bisphosphonates used to treat osteoporosis. Recent studies suggest that ALS may induce cell death and inhibit the proliferation of estrogen‐sensitive MCF‐7 breast cancer cells. The aim of this work is a combination of ALS and Trans‐activating regulatory protein (TAT) to potentiate ALS cytotoxicity against MCF‐7 breast cancer cells. ALS and TAT were prepared as nanostructured lipid carriers (NLCs). The formed NLCs were characterized for particle size and zeta potential. Cell viability was also carried out for the prepared NLCs. The results revealed that the prepared NLCs were spherical, with particle sizes of 285.2 ± 14.1 nm, with a polydispersity index of 0.51 and zeta potential of +21.1 ± 3.4 mV. The ALS %EE of the prepared NLCs was 12.2 ± 1.1%. ALS IC50 was decreased by about 30 % when compared with the raw drug. According to cell viability, The IC50 values for the treatments were as follows: ALS, 2.77 ± 0.36 μM; ALS‐TAT NLCs, 1.98 ± 0.17 μM; TAT, 1066.67 ± 21.22 μM and plain formula 10816.2 ± 112.32 μM. Which makes their combination with ALS a promising candidate for breast cancer therapy.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.